Steel Therapeutics

Focus: Steel Therapeutics is a biotechnology company based in Iowa City specializing in medicated wipes with a pipeline spanning metabolic diseases, oncology, nephrology, and cardiovascular indications. The company operates at a pre-revenue or early-stage biotech scale with minimal disclosed financial infrastructure.

Metabolic Diseases Oncology Nephrology Cardiovascular

Profile data last refreshed 9m ago · AI intelligence enriched 1w ago

Open Jobs

Should You Work at Steel Therapeutics?

AI assessment

Steel Therapeutics presents significant early-stage risk alongside limited visibility into pipeline quality, capital position, and hiring demand—suitable only for founders, deep-stage equity participants, or candidates comfortable with pre-commercial biotech uncertainty.

Why Work Here

Broad therapeutic area exposure across four major disease domains (metabolic, oncology, nephrology, cardiovascular) offers diverse scientific learning opportunities.

Data completeness

2/9 — Limited

Company HealthStrong

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Individualized anti-infective therapy

Sepsis

N/A

Clinical Trials (1)

NCT07770347Immunity in Critical Sepsis

N/A

Help build intelligence for Steel Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage positioning may provide equity upside and hands-on involvement in pipeline development for candidates willing to embrace pre-revenue risk.

Novel medicated wipe delivery platform represents differentiated technology that could attract clinical and commercial interest in underserved patient populations.

Watch Out For

No disclosed revenue, funding, employee count, or financial data suggests pre-revenue status with unclear capital runway and burn rate sustainability.
Pipeline exhibits disorganized structure with 12 programs spanning observational studies, dietary interventions, and repurposed agents—none appear to be novel proprietary candidates in active IND development.
Only 2 active job openings (both IT) and absence of R&D hiring signal minimal current growth trajectory and limited near-term career advancement opportunities.
Single Phase 3 program (prophylactic extended-field irradiation for cervical cancer) with no disclosed timelines, trial updates, or regulatory catalysts visible.

Generated by Claude from Steel Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Tamoxifen

Breast Cancer

N/A

Clinical Trials (1)

NCT04666805Effect of Endocrine Therapy Duration on Clinical Outcome of Patients With HR+ Intraductal Carcinoma of the Breast

N/A

Drug-coated balloon

Drug-Coated Balloon

N/A

acellular dermal matrix plug

Anal Fistula

N/A